Jump to navigation. We reviewed the evidence concerning the effectiveness and safety of fulvestrant in prolonging time without further progression of cancer in women with advanced hormone -sensitive breast cancer. We found nine studies testing whether or not fulvestrant is superior to other treatment options. Seventy percent of breast cancers are sensitive to hormones, and there are a variety of endocrine therapies that lower or block female hormones to treat these cancers. Fulvestrant is one such endocrine therapy that can be used to treat hormone -sensitive breast cancers by blocking oestrogen.
Postmenopausal women with hormone receptor positive breast cancer may be offered adjuvant therapy with either tamoxifen or with an aromatase inhibitor. Aromatase inhibitors belong to a class of drugs that work by reducing the levels of estrogen in the body. Even if you have stopped menstruating, your body may still produce small amounts of estrogen in the adrenal glands, fat tissue and even breast tissue.
Before the menopause, the ovaries produce the hormones oestrogen and progesterone. After the menopause, oestrogen is made in body fat. Hormone therapy is only likely to work if the breast cancer cells have oestrogen receptors ER. Your doctor checks your cancer cells for these receptors when you are diagnosed.